An autoimmune domain-reduced HCV core gene remains effective in stimulating anti-core cytotoxic T lymphocyte activity
Y LIU(University of Arkansas for Medical Sciences), Paul L. Hermonat(University of Arkansas for Medical Sciences), Dekai Zhang(Chongqing Medical University), Changxuan You(Nanfang Hospital), Hong Zheng(University of Arkansas for Medical Sciences), Ren Luo(Southern Medical University), Wenbo Zhou(Chongqing Medical University), Hung‐Jen Liu(National Chung Hsing University), Helen Kay(University of Arkansas for Medical Sciences), Hong You(Harbin Institute of Technology)
Cited by 15
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156
TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx
|Cell Calcium|2010|135
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126